You are here: Home » News-CM » Companies » News
Business Standard

Boehringer Ingelheim India and Lupin expand collaboration for co-marketing of two oral anti-diabetic drugs

Capital Market 

German based pharma major- and announced the expansion of their partnership with plans to market two new oral anti-diabetics recently approved by the of (DCGI) Gibtulio Mee (Empagliflozin+ Metformin) and Ajaduo" (+Linagliptin). Both these products belong to a novel class of oral patented in and will be launched for the first time by an Indian company.

The two products will be co-marketed simultaneously by and across under different brand names.

The +combination is the world's first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor. In addition to a strong effect on lowering blood sugar levels, it also addresses multiple pathophysiological defects in type 2 diabetes, and is a big step towards improved management of type 2 It will also help in reducing the pill burden for patients and help improve adherence to the prescribed treatment.

The + combination can be given to newly diagnosed patients at higher baseline HbAlc levels and would help manage cardiac complications in patients with type 2 with heart disease.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, July 11 2018. 10:54 IST